

# Braingate<sup>™</sup> \*: Developing a Device to Provide Motor Impaired Patients with A Novel Neural Output

Misha D. Serruya, John P. Donoghue\*, Nicholas Hatsopoulos+, Richard Van Wagenen, K. Shane Guillory, Abe Caplan, Maryam Saleh, Dan Morris, Brian W. Hatt, Timothy R. Surgenor, Gerhard M Friehs++

Cyberkinetics, Inc., Foxboro, MA, and Salt Lake City, UT. \* Brown University; +University of Chicago; ++Brown University and Rhode Island Hospital



### **Communication Requirements of Motor Impaired Patients**

\*Note: The BrainGate is not a human investigational device in the United States. An IDE application has not yet been filled with the FDA. This poster is informational only and is intended to present the overall status of development of the product at Cyberkinetics Inc.





## **Preclinical Safety**

#### Overview of non-human primate experience

39 implants in 17 macaque monkeys (February 1998-April 2003

Implant Group	Numbe r of Animal s	M1 Implants	Implant s Not MI	Minor AE (Skin Infection, Erosion, or Connector Issue)	Major AE (macranialm fection, vescular or secure)	Duration (Days)
Prior (=other coating; all locations)	13	ः14	11	22	3	1098
Recent (=parylene; all locations)	8	6	5	9	0	310
Relevant (= parylene; M1)	5	6	62	7	0	385

Three most recent implants (ongoing) 187, 250, 385 days (L, C, R)

### Long-lasting Recordings From Many Electrodes





Many Neurons Every Day (19 tests over 110 days) Blue - no recording Red - best recordings Donoghue Lab

### Histology



THIONINE STAIN



A A You

GFAP STAINING

#### Removal and Reimplantation



